T1	Participants 42 70	employed depressed patients:
T2	Participants 319 374	employed patients with major depressive disorder (MDD).
T3	Participants 383 563	Gainfully employed (≥20 h/wk) male and female outpatients with MDD were randomly assigned (2:1 ratio) to 12 weeks of double-blind treatment with desvenlafaxine 50 mg/d or placebo
T4	Participants 835 846	population.
T5	Participants 847 943	A predefined, modified ITT population (ie, those in the ITT population with baseline HAM-D₁₇
T6	Participants 1848 1883	was efficacious for treating MDD in
